Related Experiment Video
Updated: Mar 12, 2026
08:58
Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
13.3K
How I treat cryoglobulinemia
Eli Muchtar1, Hila Magen2, Morie A Gertz1
1Division of Hematology, Mayo Clinic, Rochester, MN; and.
Blood
|November 2, 2016
Summary
Cryoglobulinemia involves cryoglobulins in the blood, with types I and II/III linked to different diseases like hematologic disorders and hepatitis C. Treatment requires personalized evaluation of the underlying cause and disease severity.
Area of Science:
- Immunology
- Hematology
- Rheumatology
Background:
- Cryoglobulinemia is defined by cryoglobulins in serum, with varying composition impacting clinical presentation and etiology.
- It is classified into Type I (clonal hematologic diseases) and Type II/III (mixed cryoglobulinemia, often linked to Hepatitis C virus or systemic autoimmune diseases).
Observation:
- Clinical manifestations are diverse, including arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy.
- While some patients experience mild symptoms, a subset can develop life-threatening complications.
Findings:
- The heterogeneity of cryoglobulin composition necessitates a thorough etiological evaluation.
- Treatment strategies must be individualized based on cryoglobulin type, disease severity, underlying cause, and prior therapies.
Implications:
- Accurate diagnosis and tailored treatment are crucial for managing cryoglobulinemia and preventing frequent relapses.
- Understanding the spectrum of this condition is key to mitigating significant morbidity and cumulative organ damage.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
01:14Myocarditis III: Medical Management
295
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
01:27Peripheral Artery Disease III: Interprofessional Care
486
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
486